Safety and Efficacy of Amiodarone in a Patient With COVID-19

Nadia Castaldo; Alberto Aimo; Vincenzo Castiglione; Cristiano Padalino; Michele Emdin; Carlo Tascini

doi:10.1016/j.jaccas.2020.04.053

Safety and Efficacy of Amiodarone in a Patient With COVID-19

JACC Case Rep. 2020 Jul 15;2(9):1307-1310. doi: 10.1016/j.jaccas.2020.04.053. Epub 2020 May 29.

Authors

Nadia Castaldo¹, Alberto Aimo^{2

3}, Vincenzo Castiglione^{2

3}, Cristiano Padalino¹, Michele Emdin^{2

4}, Carlo Tascini¹

Affiliations

¹ Azienda Sanitaria Integrata del Friuli Centrale, Udine, Italy.
² Institute of Life Science, Scuola Sant'Anna Pisa, Pisa, Italy.
³ Cardiology Division, University Hospital of Pisa, Pisa, Italy.
⁴ Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Abstract

There is an urgent need for effective treatments for coronavirus disease-2019 (COVID-19). Amiodarone, like hydroxychloroquine, exerts antiviral actions by interfering with endocytosis and viral replication. Here, to our knowledge, we report the first case of a patient affected by respiratory failure related to COVID-19 who recovered after only supportive measures and a short amiodarone course. (Level of Difficulty: Beginner.).

Keywords: CAD, cationic amphiphilic drug; COVID-19; COVID-19, coronavirus disease-2019; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2; amiodarone.

Publication types

Case Reports